Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board

MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board

  • Post published:August 10, 2021
  • Post category:Press Release
Read more about the article MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology

MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology

  • Post published:August 3, 2021
  • Post category:Press Release
Read more about the article MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT

MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT

  • Post published:July 28, 2021
  • Post category:Press Release
Read more about the article MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company

MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company

  • Post published:July 8, 2021
  • Post category:Press Release
Read more about the article MindMed Included in FTSE Russell 3000® Index

MindMed Included in FTSE Russell 3000® Index

  • Post published:June 28, 2021
  • Post category:Press Release
Read more about the article MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board

MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board

  • Post published:June 23, 2021
  • Post category:Press Release
Read more about the article MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board

MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board

  • Post published:June 17, 2021
  • Post category:Press Release
Read more about the article MindMed Announces Chief Executive Officer Transition

MindMed Announces Chief Executive Officer Transition

  • Post published:June 9, 2021
  • Post category:Press Release
Read more about the article MindMed announces shareholder Meeting Results

MindMed announces shareholder Meeting Results

  • Post published:May 27, 2021
  • Post category:Press Release
Read more about the article MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing

MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing

  • Post published:May 26, 2021
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More